REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1557157
Allogeneic CART progress: platforms, current progress and limitations
Provisionally accepted
Mahshid Akhavan Rahnama1*
Ameneh Shokati2
Maryam Sanjari-pour3
Saghar Hoseinzadeh4Mohammad Ahmadvand1*Mohammad Vaezi1- 1Research Center for Cell Therapy and Hematopoietic Cell Transplantation, Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
- 2Department of Applied cell Science, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Alborz, Iran
- 3Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Alborz, Iran
- 4Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Allogenic chimeric antigen receptor T (CAR-T) cells have advantages compared to autologous T cell therapies such as availability cells for production, a suitable HLA-matched donor (if graft-vshost-disease and rejection effects are to be avoided and also lower risks associated with transduction methods in process of autologous CAR-T cells).In recent years, the additional editing and non-editing technologies are helping to make allogenic CAR-T therapies a hopeful future treatment. Universal off-the-shelf CAR-T cells can be solved key issues include preventing graft-versus-host disease (GVHD) and time consumption and other challenges faced to allogenic CAR-T cells.Here, we have highlighted the improvement in CAR-T development, particularly in engineering allogenic CAR-T, clinical practices related to these, pre-clinical and clinical studies and their successes which investigated in recent 10 years related to treatment of hematological malignancies and cancers by allogenic CAR-T cells.
Keywords: Allogeneic CAR T cells1, editing technology2, non-editing technology3, off-the-shelf CART cell4, graft-versus-host disease
Received: 08 Jan 2025; Accepted: 22 May 2025.
Copyright: © 2025 Akhavan Rahnama, Shokati, Sanjari-pour, Hoseinzadeh, Ahmadvand and Vaezi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Mahshid Akhavan Rahnama, Research Center for Cell Therapy and Hematopoietic Cell Transplantation, Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
Mohammad Ahmadvand, Research Center for Cell Therapy and Hematopoietic Cell Transplantation, Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.